Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 4, 2011 - Issue 5
Submit an article Journal homepage
364
Views
89
CrossRef citations to date
0
Altmetric
Review

Innovative clinical trial design for pediatric therapeutics

Matthew M Laughon School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
,
Daniel K Benjamin Department of Pediatrics, Duke University, Durham, NC, USA; Duke Clinical Research Institute, Durham, NC, USA;[email protected]
,
Edmund V Capparelli University of California at San Diego, San Diego, CA, USA; University of California at San Diego, San Diego, CA, USA
,
Gregory L Kearns The Children’s Mercy Hospital, Kansas City, MO, USA; The Children’s Mercy Hospital, Kansas City, MO, USA
,
Katherine Berezny Duke Clinical Research Institute, Durham, NC, USA; Duke Clinical Research Institute, Durham, NC, USA
,
Ian M Paul Penn State College of Medicine, Hershey, PA, USA; Penn State College of Medicine, Hershey, PA, USA
,
Kelly Wade Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, USA
,
Jeff Barrett Penn State College of Medicine, Hershey, PA, USA; Penn State College of Medicine, Hershey, PA, USA
,
Phillip Brian Smith Department of Pediatrics, Duke University, Durham, NC, USA; Duke Clinical Research Institute, Durham, NC, USA; Department of Pediatrics, Duke University, Durham, NC, USA; Duke Clinical Research Institute, Durham, NC, USA
&
Michael Cohen-Wolkowiez Department of Pediatrics, Duke University, Durham, NC, USA; Duke Clinical Research Institute, Durham, NC, USA; Department of Pediatrics, Duke University, Durham, NC, USA; Duke Clinical Research Institute, Durham, NC, USA
 show all
Pages 643-652 | Published online: 10 Jan 2014

References

  • Shirkey HC. Therapeutic orphans – everybody’s business. Ann. Pharmacother.40(6), 1174 (2006).
  • Choonara I. Unlicensed and off-label drug use in children: implications for safety. Expert Opin. Drug Saf.3(2), 81–83 (2004).
  • Roberts R, Rodriguez W, Murphy D et al. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA290(7), 905–911 (2003).
  • Turner S, Nunn AJ, Fielding K et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr.88(9), 965–968 (1999).
  • Avenel S, Bomkratz A, Dassieu G et al. The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch. Pediatr.7(2), 143–147 (2000).
  • O’Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics110(5), e52 (2002).
  • ’t Jong GW, Vulto AG, de Hoog M et al. A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics108(5), 1089–1093 (2001).
  • Rodriguez W, Selen A, Avant D et al. Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics121(3), 530–539 (2008).
  • Smith PB, Benjamin DK Jr, Murphy MD et al. Safety monitoring of drugs receiving pediatric marketing exclusivity. Pediatrics122(3), E628–E633 (2008).
  • Benjamin DK Jr, Smith PB, Sun MJ et al. Safety and transparency of pediatric drug trials. Arch. Pediatr. Adolesc. Med.163(12), 1080–1086 (2009).
  • Benjamin DK Jr, Smith PB, Murphy MD et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA296(10), 1266–1273 (2006).
  • Wade KC, Wu D, Kaufman DA et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob. Agents Chemother.52(11), 4043–4049 (2008).
  • Cohen-Wolkowiez M, Benjamin DK Jr, Steinbach WJ et al. Anidulafungin: a new echinocandin for the treatment of fungal infections. Drugs Today (Barc.)42(8), 533–544 (2006).
  • Hope WW, Seibel NL, Schwartz CL et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob. Agents Chemother.51(10), 3714–3719 (2007).
  • Benjamin DK Jr, Smith P, Arrieta A et al. Safety and pharmacokinetics of repeat-dose micafungin in neonates. Presented at: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 25–28 October 2008.
  • Holford N, Dosing in children. Clin. Pharmacol. Ther.87(3), 367–370 (2010).
  • Acosta EP, Jester P, Gal P et al. Oseltamivir dosing for influenza infection in premature neonates. J. Infect. Dis.202(4), 563–566 (2010).
  • Andersen DH, Blanc WA, Crozier DN et al. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics18(4), 614–625 (1956).
  • Stewart DJ. The effects of tetracyclines upon the dentition. Br. J. Dermatol.76, 374–378 (1964).
  • Burns LE, Hodgman JE, Cass AB, Fatal circulatory collapse in premature infants receiving chloramphenicol. N. Engl. J. Med.261, 1318–1321 (1959).
  • Yeh TF, Lin YJ, Huang CC et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics101(5), E7 (1998).
  • Aranda JV, Clarkson S, Collinge JM. Changing pattern of drug utilization in a neonatal intensive care unit. Am. J. Perinatol.1(1), 28–30 (1983).
  • Du W, Warrier I, Tutag Lehr V et al. Changing patterns of drug utilization in a neonatal intensive care population. Am. J. Perinatol.23(5), 279–285 (2006).
  • Kearns GL, Abdel-Rahman SM, Alander SW et al. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N. Engl. J. Med.349(12), 1157–1167 (2003).
  • Burtin P, Jacqz-Aigrain E, Girard P et al. Population pharmacokinetics of midazolam in neonates. Clin. Pharmacol. Ther.56(6 Pt 1), 615–625 (1994).
  • Anand KJ, Anderson BJ, Holford NH et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br. J. Anaesth.101(5), 680–689 (2008).
  • Pacifici GM, Labatia J, Mulla H et al. Clinical pharmacokinetics of penicillins in the neonate: a review of the literature. Eur. J. Clin. Pharmacol.65(2), 191–198 (2009).
  • Allegaert K, Peeters MY, Verbesselt R et al. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Br. J. Anaesth.99(6), 864–870 (2007).
  • Peeters MY, Allegaert K, Blussé van Oud-Alblas HJ et al. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin. Pharmacokinet.49(4), 269–275 (2010).
  • Fischer S, Bohn D, Rycus P et al. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: analysis of the Extracorporeal Life Support Organization (ELSO) registry. J. Heart Lung Transplant.26(5), 472–477 (2007).
  • Meyer DM, Jessen ME. Results of extracorporeal membrane oxygenation in children with sepsis. The Extracorporeal Life Support Organization. Ann. Thorac. Surg.63(3), 756–761 (1997).
  • Green TP, Timmons OD, Fackler JC et al. The impact of extracorporeal membrane oxygenation on survival in pediatric patients with acute respiratory failure. Pediatric Critical Care Study Group. Crit. Care Med.24(2), 323–329 (1996).
  • Lequier L, Extracorporeal life support in pediatric and neonatal critical care: a review. J. Intensive Care Med.19(5), 243–258 (2004).
  • Frenckner B, Radell P. Respiratory failure and extracorporeal membrane oxygenation. Semin. Pediatr. Surg.17(1), 34–41 (2008).
  • Rajagopal SK, Almond CS, Laussen PC et al. Extracorporeal membrane oxygenation for the support of infants, children, and young adults with acute myocarditis: a review of the Extracorporeal Life Support Organization registry. Crit. Care Med.38(2), 382–387 (2010).
  • Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin. Pharmacokinet.42(5), 403–417 (2003).
  • Southgate WM, DiPiro JT, Robertson AF. Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation. Antimicrob. Agents Chemother.33(6), 817–819 (1989).
  • Cohen P, Collart L, Prober CG et al. Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatr. Infect. Dis. J.9(8), 562–566 (1990).
  • Dodge WF, Jelliffe RW, Zwischenberger JB et al. Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther. Drug Monit.16(6), 552–559 (1994).
  • Bhatt-Mehta V, Johnson CE, Schumacher RE. Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy12(1), 28–32 (1992).
  • Munzenberger PJ, Massoud N. Pharmacokinetics of gentamicin in neonatal patients supported with extracorporeal membrane oxygenation. ASAIO Trans.37(1), 16–18 (1991).
  • Hoie EB, Swigart SA, Leuschen MP et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin. Pharm.9(9), 711–715 (1990).
  • Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob. Agents Chemother.40(5), 1139–1142 (1996).
  • Buck ML. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy18(5), 1082–1086 (1998).
  • Bhatt-Meht V, Annich G. Sedative clearance during extracorporeal membrane oxygenation. Perfusion20(6), 309–315 (2005).
  • Dagan O, Klein J, Bohn D et al. Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. Crit. Care Med.22(7), 1099–1101 (1994).
  • Mehta NM, Halwick DR, Dodson BL et al. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med.33(6), 1018–1024 (2007).
  • Mulla H, Lawson G, von Anrep C et al.In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion15(1), 21–26 (2000).
  • Drug Therapies in Neonates and Children During Extracorporeal Membrane Oxygenation (ECMO); Keep Your Eyes Open. Wildschut E (Ed.). Erasmus MC, Rotterdam, The Netherlands (2010).
  • Peters JW, Anderson BJ, Simons SH et al. Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. Intensive Care Med.31(2), 257–263 (2005).
  • Ogden CL, Carroll MD, Curtin LR et al. Prevalence of high body mass index in US children and adolescents, 2007–2008. JAMA303(3), 242–249 (2010).
  • Poggesi I, Benedetti MS, Whomsley R et al. Pharmacokinetics in special populations. Drug Metab. Rev.41(3), 422–454 (2009).
  • Srinivasan V, Nadkarni VM, Helfaer MA et al. Childhood obesity and survival after in-hospital pediatric cardiopulmonary resuscitation. Pediatrics125(3), e481–e488 (2010).
  • Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet.49(2), 71–87 (2010).
  • Sammons H. Ethical issues of clinical trials in children: a European perspective. Arch. Dis. Child94(6), 474–477 (2009).
  • de Hoog M, Schoemaker RC, Mouton JW et al. Vancomycin population pharmacokinetics in neonates. Clin. Pharmacol. Ther.67(4), 360–367 (2000).
  • Garcia B, Barcia E, Perez F et al. Population pharmacokinetics of gentamicin in premature newborns. J. Antimicrob. Chemother.58(2), 372–379 (2006).
  • Bouvier d’Yvoire M, Prieto P, Blaauboer BJ et al. Physiologically-based kinetic modelling (PBK modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. Altern. Lab. Anim.35(6), 661–671 (2007).
  • Bois FY, Jamei M, Clewell HJ. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology278(3), 256–267 (2010).
  • Bradley JS, Sauberan JB, Ambrose PG et al. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr. Infect. Dis. J.27(9), 794–799 (2008).
  • Capparelli E, Hochwald C, Rasmussen M et al. Population pharmacokinetics of cefepime in the neonate. Antimicrob. Agents Chemother.49(7), 2760–2766 (2005).
  • Pullen J, Stolk LM, Nieman FH et al. Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates. Ther. Drug Monit.28(2), 226–231 (2006).
  • Benjamin DK Jr, Smith PB, Arrieta A et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin. Pharmacol. Ther.87(1), 93–99 (2010).
  • Smith PB, Walsh TJ, Hope W et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr. Infect Dis. J.28(5), 412–415 (2009).
  • Acosta EP, Brundage RC, King JR et al.; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin. Pharmacol. Ther.81(6), 867–872 (2007).
  • Ahsman MJ, Wildschut ED, Tibboel D et al. Microanalysis of β-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates. Antimicrob. Agents Chemother.53(1), 75–80 (2009).
  • Jung BH, Rezk NL, Bridges AS et al. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr.21(10), 1095–1104 (2007).
  • Denooz R, Charlier C. Simultaneous determination of five β-lactam antibiotics (cefepim, ceftazidim, cefuroxim, meropenem and piperacillin) in human plasma by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.864(1–2), 161–167 (2008).
  • Holt DE, de Louvois J, Hurley R et al. A high performance liquid chromatography system for the simultaneous assay of some antibiotics commonly found in combination in clinical samples. J. Antimicrob. Chemother.26(1), 107–115 (1990).
  • Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal. Chem.81(4), 1557–1563 (2009).
  • Cheung CY, van der Heijden J, Hoogtanders K et al. Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation. Transpl. Int.21(2), 140–145 (2008).
  • Allanson AL, Cotton MM, Tettey JN et al. Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring. J. Pharm. Biomed. Anal.44(4), 963–969 (2007).
  • Hibberd SG, Alveyn C, Coombes EJ et al. Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. Br. J. Clin. Pharmacol.22(3), 337–341 (1986).
  • Suyagh MF, Iheagwaram G, Kole PL et al. Development and validation of a dried blood spot-HPLC assay for the determination of metronidazole in neonatal whole blood samples. Anal. Bioanal. Chem.397(2), 687–693 (2010).
  • Suyagh M, Collier PS, Millership JS et al. Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling. Pediatrics127(2), e367–e374 (2011).
  • Leeder JS, Kearns GL, Spielberg SP et al. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J. Clin. Pharmacol.50(12), 1377–1387 (2010).
  • Kearns GL, Andersson T, James LP et al. Omeprazole disposition in children following single-dose administration. J. Clin. Pharmacol.43(8), 840–848 (2003).
  • Kearns GL, Blumer J, Schexnayder S et al. Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. J. Clin. Pharmacol.48(11), 1356–1365 (2008).
  • Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab. Dispos.38(6), 894–897 (2010).
  • Capparelli EV, Englund JA, Connor JD et al. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J. Clin. Pharmacol.43(2), 133–140 (2003).
  • Wade KC, Benjamin DK Jr, Kaufman DA et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr. Infect. Dis. J.28(8), 717–723 (2009).
  • Barrett J. Modeling and Simulation. In: Pediatric Research and Development, in Clinical Trial Simulations: Applications & Trends. Kimko H, Peck C (Eds). Springer Science + Business Media, NY, USA (2011).
  • Huisman-de Boer JJ, van den Anker JN, Vogel M et al. Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks. Antimicrob. Agents Chemother.39(2), 431–434 (1995).
  • Peltola H, Ukkonen P, Saxen H et al. Single-dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in children. Pediatrics101(4 Pt 1), 658–662 (1998).
  • Abdel-Rahman SM, Benziger DP, Jacobs RF et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr. Infect. Dis. J.27(4), 330–334 (2008).
  • Upadhyaya P, Bhatnagar V, Basu N. Pharmacokinetics of intravenous metronidazole in neonates. J. Pediatr. Surg.23(3), 263–265 (1988).
  • Smith P, Walsh T, Hope W et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Presented at: Annual Pediatric Academic Societies Meeting, 2008. Honolulu, HI, USA, 2–6 May 2008.
  • Clark RH, Bloom BH, Spitzer AR et al. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics117(6), 1979–1987 (2006).
  • Husain A, Loehle JA, Hein DW. Clinical pharmacogenetics in pediatric patients. Pharmacogenomics8(10), 1403–1411 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.